Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Mutations in β-Tubulin Map to Domains Involved in Regulation of Microtubule Stability in Epothilone- resistant Cell Lines1

Lifeng He, Chia-Ping Huang Yang and Susan Band Horwitz
Lifeng He
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Ping Huang Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Band Horwitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Chemical structures of Taxol and the Epos.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    HeLa.EpoB1.8 cells are dependent on either the Epos or the taxanes for growth. In the presence of low nanomolar concentrations of Taxol, Taxotere, Epo A, or Epo B, there is an approximate 1.5- to 2-fold increase in cell growth compared with cells grown in the absence of drug. Discodermolide does not rescue the growth of HeLa.EpoB1.8 cells. Error bars were omitted for clarity. SD did not exceed 5%.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Epo-resistant cell lines do not express the MDR1 gene. Total RNA was prepared from Epo-resistant cells and examined for the expression of the MDR1 gene by RT-PCR. SKVLB1, a cell line that overexpresses the MDR1 gene, was used as a positive control, and the β2M gene was used as a control for the quality of the samples. Lane 1, A549; Lane 2, A549.EpoB40; Lane 3, HeLa; Lane 4, HeLa.EpoA9; Lane 5, HeLa.EpoB1.8; Lane 6, SKOV3; Lane 7, SKVLB1.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Microtubule protein from A549.EpoB40 cells does not polymerize as well as MTP from A549 cells in the presence of Epo B. Cell lysates prepared from A549 and A549.EpoB40 cells were incubated with the indicated concentrations of Epo B at 37°C for 30 min. Microtubule polymers were centrifuged, and the amount of soluble microtubule protein remaining in the supernatant was determined by Western blot analysis and densitometry as an indication of the level of microtubule assembly. Bars, SD.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Modeling of mutations in β-tubulin. A, B292Gln to Glu, B173Pro to Ala, and B422Tyr to Tyr/Cys mutations are located near the M-loop, the GDP binding site, and the COOH terminus of β-tubulin, respectively. B, B292Gln is close to the M-loop and Thr-274, an amino acid residue that forms part of the Taxol/Epo binding pocket (22, 23). C, B173Pro is on the loop forming part of the nucleotide-binding pocket in β-tubulin. Another amino acid on the loop, B171, is also a Pro. D, the H11 and H12 helixes form the external surface of the microtubule polymer and provide binding sites for MAPs and motor proteins. B422Tyr is located on the H12 helix.

Tables

  • Figures
  • Table 1

    Drug resistance profile of A549.EpoB40 cells.

    IC50s were determined after 72 h of incubation with the indicated drugs. The IC50 of A549.EpoB40 cells was divided by the IC50 of A549 cells to indicate the fold decrease or increase in drug sensitivity.

    CompoundIC50 (nm)Fold
    A549A549.EpoB40
    Epo B0.96 ± 0.1191.50 ± 3.8895
    Epo A1.89 ± 0.26136.91 ± 4.7172
    Taxol3.12 ± 0.3667.96 ± 15.4022
    Taxotere1.34 ± 0.3916.87 ± 3.9113
    Discoa7.68 ± 0.6416.60 ± 2.542
    VBL2.31 ± 0.081.26 ± 0.470.5
    CLC16.86 ± 0.6310.24 ± 1.030.6
    • ↵a Disco, discodermolide; VBL, vinblastine; CLC, colchicine.

  • Table 2

    Drug resistance profile of HeLa.EpoA9 and HeLa.EpoB1.8 cells.

    IC50s were determined after 72 h of incubation with the indicated drugs. The IC50 of HeLa.EpoA9 and HeLa.EpoB1.8 cells were divided by the IC50 of HeLa cells to indicate the fold decrease or increase in drug sensitivity.

    CompoundHeLa
    HeLa.EpoA9HeLa.EpoB1.8
    IC50 (nm)IC50 (nm)FoldIC50 (nm)Fold
    Epo A4.02 ± 0.019.95 ± 0.192.56.18 ± 0.041.5
    EpoB1.96 ± 0.483.40 ± 0.081.74.41 ± 0.162.3
    Taxol1.68 ± 0.0110.70 ± 0.846.44.75 ± 0.032.8
    Taxotere1.42 ± 0.057.84 ± 0.155.54.89 ± 0.063.4
    Discoa7.54 ± 0.1916.01 ± 0.462.16.70 ± 0.920.9
    VBL0.95 ± 0.080.81 ± 0.050.91.55 ± 0.071.6
    CLC10.80 ± 0.786.24 ± 0.100.64.52 ± 0.180.4
    • ↵a Disco, discodermolide; VBL, vinblastine; CLC, colchicine.

  • Table 3

    Doubling time for Epo-sensitive and Epo-resistant cell lines.

    Cells (40,000 cells/well) were seeded in a six-well plate and allowed to grow to 80% confluency. The total number of cells in each well was counted, and the length of incubation was used to obtain the doubling time.

    Cell lineDoubling time (h)Increase (%)
    A54923.5
    A549.EpoB4031.835
    HeLa19.5
    HeLa.EpoA921.510
    HeLa.EpoB1.843.3122
  • Table 4

    Class I β-tubulin mutations in Epo-resistant cell lines.

    Total RNA was prepared from Epo-resistant cell lines and the parental drug-sensitive cell lines. RNA was reverse transcribed to cDNA. The class I β-tubulin gene was amplified by PCR and sequenced with four pairs of primers. A mutation is noted after comparison to both the published sequence and the class I β-tubulin in the drug-sensitive parental cell line.

    Cell lineAmino acidCodon
    A549.EpoB40B292Gln → GluCAG → GAG
    HeLa.EpoA9B173Pro → AlaCCC → GCC
    HeLa.EpoB1.8B422Tyr → Tyr/CysTAT → TAT/TGT
PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (1)
November 2001
Volume 1, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations in β-Tubulin Map to Domains Involved in Regulation of Microtubule Stability in Epothilone- resistant Cell Lines1
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mutations in β-Tubulin Map to Domains Involved in Regulation of Microtubule Stability in Epothilone- resistant Cell Lines1
Lifeng He, Chia-Ping Huang Yang and Susan Band Horwitz
Mol Cancer Ther November 1 2001 (1) (1) 3-10;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mutations in β-Tubulin Map to Domains Involved in Regulation of Microtubule Stability in Epothilone- resistant Cell Lines1
Lifeng He, Chia-Ping Huang Yang and Susan Band Horwitz
Mol Cancer Ther November 1 2001 (1) (1) 3-10;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement